바로가기메뉴

우측 토글메뉴 닫기
RT Board
RT Story
Accomplishments
Radiation Statistics
Radiation Encyclopedia
Recommended Site
News
RT News
Event Announcement
Notice
RT Information
Patent NDSL
Research Paper NDSL
Laws and Regulations
Publications
Issue Paper
Legal Analysis Report
Company Support
Company Promotion
Product Promotion
About RATIS
About RATIS
Vision
CI
Sitemap
How to Visit RATIS
Customer Center
Q&A
FAQ
Privacy Policy
Terms and Conditions
Login
SITEMAP

이전 페이지로 가기RT News

상세내용
내용보기
Title Belgium’s IRE And SCK-CEN To Cooperate In Fight Against Prostate Cancer
Sources The Independent Nuclear News Agency
Sources URL https://www.nucnet.org/news/belgium-s-ire-and-sck-cen-to-cooperate-in-fight-against-prostate-cancer-2-4-2020
Date of
Registration
2020-03-16 Views 1

Details

Belgium’s National Institute for Radioelements (IRE) and nuclear research centre SCK-CEN have signed an agreement to join efforts on the production of lutetium-177 (Lu-177), a medical radioisotope mainly used to treat prostate cancer.
In a joint statement the two organisations said the use of Lu-177 is one of the most promising approaches to treating prostate cancer.
Currently, the medical radioisotope is used in hospitals to treat neuroendocrine cancers, the statement said.
소식 및 동향
Belgium’s IRE And SCK-CEN To Cooperate In Fight Against Prostate Cancer
Sources The Independent Nuclear News Agency
Sources URL https://www.nucnet.org/news/belgium-s-ire-and-sck-cen-to-cooperate-in-fight-against-prostate-cancer-2-4-2020
Date of Registration 2020-03-16 Views 1
Details
Belgium’s National Institute for Radioelements (IRE) and nuclear research centre SCK-CEN have signed an agreement to join efforts on the production of lutetium-177 (Lu-177), a medical radioisotope mainly used to treat prostate cancer. In a joint statement the two organisations said the use of Lu-177 is one of the most promising approaches to treating prostate cancer. Currently, the medical radioisotope is used in hospitals to treat neuroendocrine cancers, the statement said.